Pharma BD Deal Intelligence
Valeant's $2.6B Medicis acquisition closed but never held together: within 18 months it flipped the injectables business (Restylane, Dysport) to Galderma for $1.4B, while flagship Solodyn sales collapsed ~40% in a single quarter amid Valeant's own channel chaos, foreshadowing the roll-up model that later destroyed Valeant itself.
Valeant Revives Growth Plan With $2.6 Billion Medicis Deal. Valeant's stock rose 15 percent, its biggest gain since January 2011 and highest close on record,…
Valeant scoops up Medicis' dermatology portfolio in $2.6B buyout, leaping to the top tier of dermatology and aesthetics through another debt-funded acquisition.
Zacks Investment Research framed the closing as broadly positive: the combination created a global dermatology leader and was expected to be immediately…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Valeant acquired Medicis at $44/share cash for $2.6B (39% premium). Combined dermatology/aesthetics franchise pro forma 2012 US revenue >$1.7B. Identified $225M cost synergies within 6 months.
Assessment window: 5yr post-close.
$1.7B Combined Valeant/Medicis pro forma 2012 US revenue
Dermatology and aesthetics span both medical conditions (acne, rosacea, actinic keratosis) and lifestyle/cash-pay aesthetics (wrinkle correction, dermal fillers, neurotoxins). Acne alone affects up to 50M Americans annually, and the high gross-margin nature of branded derm products plus cash-pay aesthetics has historically made the category attractive to specialty pharma roll-ups.
At the time of Valeant's September 2012 acquisition of Medicis, the dermatology and aesthetics space was undergoing rapid consolidation. Medicis' Solodyn (extended-release minocycline) was the lead acne franchise, competing with Galderma's Oracea (doxycycline) and Allergan's Aczone, with generic minocycline as a constant pricing pressure. In aesthetics, Restylane and Perlane (hyaluronic acid fillers) competed directly with Allergan's Juvederm and Galderma/Q-Med portfolios; Dysport (abobotulinumtoxinA) was the principal challenger to Allergan's market-leading Botox; and Zyclara (imiquimod 3.75%) competed with Graceway's Aldara in actinic keratosis. The deal was Valeant's 15th of 2012 (>$3.5B aggregate spend) and consolidated the company as a top-three global dermatology player alongside Galderma and Stiefel/GSK. CEO Mike Pearson explicitly framed it as the cornerstone of becoming 'a leader in the dermatology field,' targeting $225M in cost synergies within six months — consistent with Valeant's R&D-light, acquisition-driven model. Analyst sentiment was broadly positive on the strategic and financial logic, though the same model later drew scrutiny over Solodyn pricing practices and the 2015 Philidor specialty-pharmacy controversy that ultimately unwound much of the thesis. (Sources: https://en.wikipedia.org/wiki/Medicis_Pharmaceutical; https://www.theglobeandmail.com/report-on-business/valeant-snaps-up-medicis-for-26-billion/article4516534/)
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Valeant Pharmaceuticals International, Inc. / Medicis Pharmaceutical Corporation (this deal) | 2012 | $2.6B | 33 |
| Valeant Pharmaceuticals International, Inc. / Dow Pharmaceutical Sciences, Inc. | 2009 | $285M | 66 |
| Valeant Pharmaceuticals International, Inc. / iNova Pharmaceuticals | 2011 | $700M | 63 |
| Valeant Pharmaceuticals International, Inc. / Xcel Pharmaceuticals, Inc. | 2005 | $280M | 42 |
| Valeant Pharmaceuticals International, Inc. / Dermik Laboratories (Sanofi dermatology unit) | 2011 | $425M | 36 |
| Valeant Pharmaceuticals International, Inc. / Bausch + Lomb | 2013 | $8.7B | 36 |
| Valeant Pharmaceuticals International, Inc. / PreCision Dermatology, Inc. | 2014 | $475M | 23 |
← Browse all deals · How we score deals
More: 2012 deals · Valeant Pharmaceuticals International, Inc. deals · Dermatology deals